ArticleAmerican journal of translational research2026
Clinical efficacy of Conbercept combined with pars plana vitrectomy for proliferative diabetic retinopathy.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy of Conbercept combined with pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy (PDR).
methodsA total of 118 PDR patients were retrospectively selected and allocated to a control group (n=52, undergoing PPV only) and an observation group (n=66, receiving preoperative intravitreal Conbercept combined with PPV) according their treatment regimen. Outcome measures included visual acuity improvement, best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), surgical indices (intraoperative electrocautery frequency, eyes with intraoperative bleeding, silicone oil usage, and iatrogenic retinal injury), preoperative aqueous humor cytokine levels, postoperative complications, and life quality.
resultsPostoperative visual acuity was notably better in the observation group compared with the control group. Both groups showed significant reductions in BCVA, CRT, and IOP after surgery, with the observation group displaying even lower values. Intraoperative electrocautery frequency, eyes with bleeding, silicone oil usage, incidence of iatrogenic retinal injury, and preoperative aqueous humor cytokine levels were lower in the observation group compared with the control group. Moreover, the observation group also reported a lower overall complication rate and better postoperative quality of life.
conclusionPreoperative intravitreal Conbercept combined with PPV offers superior clinical benefits for PDR patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.